CBD has strong evidence for seizures but weak evidence for most other claims

Refractory seizure control has strong evidence. Acute CBD before anxiety-provoking events and chronic CBD for schizophrenia are promising but not proven. For most other conditions CBD is marketed for, evidence is weak or very weak. CBD is not risk-free: adverse effects include somnolence and GI symptoms, drug interactions occur, liver function test elevations have been documented, and potential effects on suicidal ideation need further study.

Review of human clinical studies evaluating CBD across multiple conditions, with assessment of evidence quality for each indication.

CBD products are widely available and marketed for dozens of conditions, but the gap between marketing claims and actual evidence is substantial. This review helps separate what is proven from what is speculative.

The quality gap between FDA-approved CBD (Epidiolex) and unregulated CBD products means consumers may not be getting the dose or purity they expect, adding uncertainty beyond the already limited evidence.

Narrative review. Evidence quality varies widely across conditions. Non-FDA-approved products have unknown quality, making it difficult to draw conclusions from studies using them.